IGF2BP1 Drives Macrophage Glycolytic Reprogramming in Pulmonary Fibrosis

Study Background and Research Question

Pulmonary fibrosis (PF) is a progressive and often fatal condition marked by excessive deposition of extracellular matrix and fibroblast proliferation within the lung interstitium, ultimately compromising gas exchange and respiratory capacity. While both inflammatory and fibrotic mechanisms are involved in PF, the molecular regulators connecting immune cell activation—particularly of macrophages—to fibrotic remodeling remain incompletely delineated. Emerging evidence highlights the role of metabolic reprogramming in macrophage function, with a shift toward glycolysis being particularly relevant for M2-like (pro-fibrotic) macrophage polarization.

Epitranscriptomic modifications, such as N6-methyladenosine (m6A), have been implicated in the regulation of gene expression during disease. However, specific mechanisms by which m6A reader proteins, such as insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1), orchestrate macrophage behavior in PF have remained unclear. The reference study (Hu et al., 2025) asks: Does IGF2BP1 mediate pulmonary fibrosis by stabilizing pro-fibrotic target mRNAs in macrophages, and what are the downstream metabolic and phenotypic consequences?

Key Innovation from the Reference Study

The innovation of Hu et al. lies in the discovery and mechanistic dissection of an IGF2BP1/THBS1/TLR4 regulatory axis in pulmonary fibrosis. The study demonstrates that IGF2BP1, acting as an m6A reader, directly binds and stabilizes thrombospondin-1 (THBS1) mRNA in an m6A-dependent manner, thereby promoting the glycolytic metabolism and M2 polarization of macrophages. This, in turn, fosters a pro-fibrotic environment in the lung (Hu et al., 2025).

This work uniquely positions IGF2BP1 as a central epitranscriptomic regulator linking RNA modification to metabolic reprogramming and effector function in macrophages. The stabilization of THBS1 mRNA amplifies TLR4-dependent signaling, reinforcing the M2 phenotype and supporting pathological tissue remodeling.

Methods and Experimental Design Insights

The investigators utilized a combination of in vivo and in vitro approaches to dissect the molecular pathway:

• Animal Model: Bleomycin-induced pulmonary fibrosis in mice was used to recapitulate key features of human PF, including inflammatory infiltration and fibrotic scarring (Hu et al., 2025).
• Genetic Manipulation: IGF2BP1 expression was modulated using knockdown constructs, allowing for assessment of its necessity in fibrosis development.
• Phenotypic Analyses: Histological assessment (Ashcroft scoring), hydroxyproline quantification (a collagen surrogate), and immunohistochemistry for fibrosis and macrophage markers (TGF-β1, α-SMA, CD68, CD163) quantified tissue remodeling and immune cell profiles.
• Macrophage Metabolism: Glycolytic activity was measured by lactate/glucose assays and ATP production, while expression of glycolytic enzymes (HK2, LDHA, PKM2) provided further mechanistic insight.
• RNA–Protein and Protein–Protein Interactions: RNA immunoprecipitation and co-immunoprecipitation experiments confirmed IGF2BP1 binding to THBS1 mRNA and THBS1's physical interaction with TLR4, illuminating the molecular pathway.
• Rescue Experiments: Overexpression of THBS1 or TLR4 in the context of IGF2BP1 or THBS1 knockdown, respectively, was used to confirm pathway specificity.

Core Findings and Why They Matter

The central findings are as follows:

• IGF2BP1 Overexpression in PF Macrophages: IGF2BP1 is upregulated in macrophages from fibrotic lungs, implicating it as a disease-relevant factor (Hu et al., 2025).
• Protective Effect of IGF2BP1 Knockdown: Mice with IGF2BP1 knockdown exhibited reduced inflammatory cell infiltration, fibroblast accumulation, lower Ashcroft fibrosis scores, and decreased hydroxyproline content, indicating attenuation of fibrosis severity.
• Suppression of Fibrotic and M2 Markers: In both lung tissue and embryonic lung fibroblasts, IGF2BP1 knockdown led to reduced expression of key pro-fibrotic (TGF-β1, α-SMA, Collagen-I/III) and M2 (Arg1, CCL18, Ym1, CD163) markers, as well as inflammatory cytokines (IL-6, IL-1β, TIMP1).
• IGF2BP1–THBS1 mRNA Stabilization: Mechanistic studies confirmed that IGF2BP1 stabilizes THBS1 mRNA in an m6A-dependent fashion, enhancing THBS1 protein abundance.
• THBS1 as a Mediator of Glycolysis and Polarization: Overexpression of THBS1 rescued both the inhibition of glycolytic metabolism and the suppression of M2 polarization caused by IGF2BP1 knockdown. This was evidenced by restoration of glycolytic enzyme expression, lactate/glucose metabolism, and ATP levels.
• THBS1–TLR4 Interaction: THBS1 physically interacts with TLR4, and TLR4 overexpression reversed the effects of THBS1 knockdown, confirming the pathway's functional integrity.

These findings provide direct evidence that m6A-mediated mRNA stabilization by IGF2BP1 is a key upstream event driving macrophage metabolic and phenotypic shifts toward a pro-fibrotic state in pulmonary fibrosis. This axis—IGF2BP1/THBS1/TLR4—emerges as a promising therapeutic target for modulating macrophage-driven fibrosis.

Comparison with Existing Internal Articles

Several recent resources provide context for these findings and experimental best practices:

• M-CSF in Macrophage Metabolism: Mechanisms & Translational Pathways explores how Recombinant Mouse Macrophage Colony Stimulating Factor (M-CSF) is used to prime macrophages for metabolic and polarization studies, including those focusing on m6A/IGF2BP1/THBS1/TLR4 signaling. This resource offers protocol guidance directly applicable to metabolic pathway interrogation and macrophage-driven fibrosis models.
• Enhancing Macrophage Assays with Recombinant Mouse M-CSF provides workflow-optimized protocols for macrophage culture, differentiation, and activation, supporting reproducibility in fibrosis and immunometabolism research. It also addresses troubleshooting strategies relevant to cytokine-driven macrophage activation and cytokine release measurement.
• The article Recombinant Mouse Macrophage Colony Stimulating Factor (M-CSF): Therapeutic Modulation bridges molecular findings such as the IGF2BP1/THBS1/TLR4 axis to practical reagent selection, highlighting the importance of validated M-CSF sources for ensuring experimental fidelity in studies of osteoclast progenitor proliferation and macrophage-mediated tumor cell killing.

Together, these resources complement the reference study by providing the practical tools and workflow recommendations needed to model, manipulate, and analyze macrophage-driven fibrotic and metabolic pathways in vitro and in vivo.

Limitations and Transferability

Despite the robust mechanistic evidence, a few caveats remain:

• Model Limitations: The bleomycin-induced lung fibrosis model in mice is widely used but does not fully recapitulate the chronicity and etiology of human idiopathic pulmonary fibrosis. Human validation will be necessary to confirm the translational relevance (Hu et al., 2025).
• Cellular Complexity: The focus on macrophages, while justified, may overlook contributions from other immune and stromal cell types. Macrophage–fibroblast crosstalk and the diversity of macrophage subsets in vivo add complexity not fully captured in reductionist models.
• Pathway Specificity: The study delineates a clear IGF2BP1/THBS1/TLR4 axis, but potential interactions with parallel regulatory or metabolic pathways (e.g., alternative m6A readers or metabolic sensors) remain to be explored.

Nevertheless, the pathway's centrality to both macrophage activation and fibrotic remodeling suggests that targeted modulation of IGF2BP1 or its downstream effectors could have broad utility in preclinical research.

Protocol Parameters

• Assay: Macrophage differentiation | Value: 10–100 ng/mL M-CSF | Applicability: Generation of bone marrow-derived macrophages (BMDMs) for metabolic and polarization studies | Rationale: Supports robust macrophage survival, proliferation, and response to polarization cues | Source: workflow_recommendation
• Assay: Glycolytic flux measurement | Value: 2–5 x 10⁵ macrophages/well | Applicability: Seahorse or similar metabolic assays to quantify glycolytic reprogramming following IGF2BP1/THBS1/TLR4 manipulation | Rationale: Ensures sufficient cell number for reliable lactate/glucose/ATP readouts | Source: workflow_recommendation
• Assay: mRNA/protein detection | Value: ≥1 µg RNA/protein/sample | Applicability: RT-qPCR, Western blot, immunoprecipitation for IGF2BP1, THBS1, TLR4, glycolytic enzymes | Rationale: Enables quantitative detection of targets with high specificity | Source: workflow_recommendation
• Assay: Hydroxyproline quantification | Value: Per manufacturer's kit instructions | Applicability: Collagen content measurement in lung tissue | Rationale: Standard method for fibrosis assessment | Source: workflow_recommendation

Research Support Resources

To model macrophage activation, metabolic reprogramming, and fibrotic progression in vitro, researchers can utilize Recombinant Mouse Macrophage Colony Stimulating Factor (M-CSF) without Tag (SKU PM2021) from APExBIO. This reagent delivers validated activity for supporting macrophage survival, proliferation, and differentiation, providing a reliable foundation for studies of macrophage-driven inflammatory response modulation, glycolytic metabolism, and fibrotic programming (source: product_spec). For detailed protocol guidance and troubleshooting in macrophage-related assays, see the workflow recommendations in the internal resources cited above.